Oxis appoints new SAB member
This article was originally published in Scrip
Oxis International, a biotechnology company focused on cannabinoid therapy development and commercialization, has named Dr Lisa A Haile a member of the scientific advisory board for its wholly owned subsidiary, Oxis Biotech. Dr Haile currently serves as co-chair, global life sciences sector at DLA Piper, where she is also a member of the firm's executive committee. She has specific technical expertise in molecular biology and immunology.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.